23 of Aalto Startup Center’s ecosystem startups are attending the Arctic15 event. Arctic15 is a Startup Investor Event and a meeting spot for startup entrepreneurs, investors, corporates and media from 60+ countries.
Who are you and what do you do?
hentoTouch: We’re hentoTouch and we’re developing a discreet neuromodulating device for alcohol relapse prevention.
What kind of team do you have at the moment?
hentoTouch: We are under Aalto University with a core team of three people, and two master’s theses workers as well as Aalto Life Science Technologies student team working around the subject.
What is your innovation?
hentoTouch: A non-invasive & non-pharmacological medical device for C-Tactile neural activation, increasing the tolerance to stress- and cue-induced alcohol craving and preventing relapses.
What kind of problem does your innovation solve?
hentoTouch: Alcohol use disorder (aud) is one of the biggest health threats, causing an economic burden of over €1tn and 3m deaths annually. Aud is one of the most under-treated mental disorder, as 90% of the patients do not receive any treatment (u.s., fin) and as there is a 85% relapse rate, showing low efficacy of existing therapies.
What is your idea’s impact for society?
hentoTouch: € 730m, that is 73% of the economic burden is paid by companies due to lowered work efficacy. Our focus is on occupational healthcare and early intervention that will lead to the biggest quality of life improvements as well as cost savings for companies, healthcare and society also covering social aspects.
What are your main Sustainable Development Goals and why?
Promote mental health and well-being: Goal 3.4* – By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being.
*Source: United Nations: sdgs.un.org/goals
What are you currently looking for and what are your next steps?
hentoTouch: We’re seeking for 1st seed stage investors for seed round Q3 2023.